临床进展说明:芬诺巴比塔尔用于治疗戒酒综合征
Thad E Abrams1,2, Matthew V Ronan3,4
1Center for Access & Delivery Research and Evaluation (CADRE), Iowa City VA Health Care System, Iowa City, Iowa, USA.
Journal of hospital medicine
|May 30, 2025
概括
芬诺巴比塔尔是一种安全有效的替代品,用于管理在住院患者中酒精戒断综合征 (AWS) 的奔类药物. 虽然证据有限,但它显示了AWS治疗的前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 临床实践 临床实践
背景情况:
- 酒精戒断综合征 (AWS) 是住院患者经常出现的临床问题.
- 对AWS的治疗范式已经发展,包括诸如phenobarbital. barbiturates等药物.
- 芬诺巴比塔尔被认为是一种辅助或替代性单疗法,用于二.
研究的目的:
- 评估芬巴比他在治疗酒精戒断综合征方面的安全性和有效性.
- 审查现有证据,支持在AWS治疗中使用巴比他.
- 为AWS提供有关巴比他的临床实践指南.
主要方法:
- 对AWS的巴比塔尔现有文献的审查.
- 证据分析关于安全性和疗效的证据与二zepines相比.
- 考虑像美国成医学协会 (ASAM) 这样的专业机构的建议.
主要成果:
- 有限但足够的证据表明,在AWS中,芬诺巴比塔尔的安全性和有效性.
- 芬诺巴尔比他可以作为替代性单疗法用于二.
- 美国成医学协会 (ASAM) 支持在特定的AWS环境中使用.
结论:
- 芬诺巴比他 (phenobarbital) 是一种可行的替代性治疗选择,用于治疗酒精戒断综合征.
- 可能需要进一步的研究来扩大AWS中巴比他的证据基础.
- 临床实践应根据当前的证据和指导方针,考虑在AWS管理中使用巴比他.
相关概念视频
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
695
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
695
CNS Depressants: Barbiturates and Benzodiazepines
1.2K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.2K
Sedatives and Hypnotics Drugs: Barbiturates
957
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
957
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
CNS Depressants: Alcohol and Nicotine
1.1K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.1K
Psychosis: Goals of Pharmacotherapy
476
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
476


